CYP1A1 common gene polymorphisms and ischemic stroke risk: a meta-analysis and a structural examination.

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY Personalized medicine Pub Date : 2023-05-01 DOI:10.2217/pme-2022-0113
Mohammad Karimian, Faezeh Karimnia
{"title":"CYP1A1 common gene polymorphisms and ischemic stroke risk: a meta-analysis and a structural examination.","authors":"Mohammad Karimian,&nbsp;Faezeh Karimnia","doi":"10.2217/pme-2022-0113","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> CYP1A1 is a metabolizing enzyme and key polymorphisms in its gene may contribute to the risk of ischemic stroke. This study aimed to investigate the association of the rs4646903 and rs1048943 polymorphisms of <i>CYP1A1</i> with stroke risk in a meta-analysis and a bioinformatic approach. <b>Materials & methods:</b> An electronic search was conducted and, after the screening procedure, six eligible studies were included in the meta-analysis. Some bioinformatic tools were employed to analyze the effects of rs4646903 and rs1048943 on <i>CYP1A1</i> gene function. <b>Results:</b> There was a significant association between rs4646903 and the reduced risk of ischemic stroke, whereas there was no significant association for rs1048943. <i>In silico</i> analysis showed that rs4646903 and rs1048943 polymorphisms could affect the gene expression and cofactor affinity, respectively. <b>Conclusion:</b> Based on these results, rs4646903 may be a protective genetic factor against ischemic stroke.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 3","pages":"271-281"},"PeriodicalIF":1.7000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2022-0113","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: CYP1A1 is a metabolizing enzyme and key polymorphisms in its gene may contribute to the risk of ischemic stroke. This study aimed to investigate the association of the rs4646903 and rs1048943 polymorphisms of CYP1A1 with stroke risk in a meta-analysis and a bioinformatic approach. Materials & methods: An electronic search was conducted and, after the screening procedure, six eligible studies were included in the meta-analysis. Some bioinformatic tools were employed to analyze the effects of rs4646903 and rs1048943 on CYP1A1 gene function. Results: There was a significant association between rs4646903 and the reduced risk of ischemic stroke, whereas there was no significant association for rs1048943. In silico analysis showed that rs4646903 and rs1048943 polymorphisms could affect the gene expression and cofactor affinity, respectively. Conclusion: Based on these results, rs4646903 may be a protective genetic factor against ischemic stroke.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CYP1A1常见基因多态性与缺血性卒中风险:荟萃分析和结构检查。
目的:CYP1A1是一种代谢酶,其基因的关键多态性可能与缺血性卒中的风险有关。本研究旨在通过荟萃分析和生物信息学方法探讨CYP1A1基因rs4646903和rs1048943多态性与卒中风险的关系。材料与方法:进行电子检索,经过筛选程序,6项符合条件的研究被纳入meta分析。利用生物信息学工具分析rs4646903和rs1048943对CYP1A1基因功能的影响。结果:rs4646903与缺血性卒中风险降低有显著相关性,而rs1048943与缺血性卒中风险降低无显著相关性。结果表明,rs4646903多态性和rs1048943多态性分别影响基因表达和辅因子亲和力。结论:rs4646903可能是缺血性脑卒中的保护性遗传因子。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Personalized medicine
Personalized medicine 医学-药学
CiteScore
3.30
自引率
4.30%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
期刊最新文献
Challenges and opportunities in building a health economic framework for personalized medicine in oncology. Developing and validating noninvasive prenatal testing for de novo autosomal dominant monogenic diseases in Vietnam. Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems. Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1